LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 112

Search options

  1. Book: Dubois' lupus erythematosus and related syndromes

    Wallace, Daniel Jeffrey / Hahn, Bevra

    2019  

    Abstract: For more than 50 years, Dubois' Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical ...

    Title variant Lupus erythematosus and related syndromes
    Author's details editors Daniel J. Wallace, Bevra Hannahs Hahn ; associated editors Mary K. Crow [und 5 weitere]
    Abstract "For more than 50 years, Dubois' Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical management, the updated 9th Edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a logical, clearly written, user-friendly manner. It's an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes"
    Keywords Lupus Erythematosus, Systemic ; Lupus Erythematosus, Cutaneous
    Language English
    Size xv, 800 Seiten, Illustrationen, 28 cm
    Edition Ninth edition
    Publisher Elsevier
    Publishing place Edinburgh
    Publishing country Great Britain
    Document type Book
    Note Zugang zu zusätzlichem Online-Material über Code
    HBZ-ID HT019998366
    ISBN 978-0-323-47927-1 ; 0-323-47927-8
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: CD8

    Singh, Ram P / Bischoff, David S / Hahn, Bevra H

    Rheumatology and immunology research

    2021  Volume 2, Issue 3, Page(s) 147–156

    Abstract: T regulatory cells ( ... ...

    Abstract T regulatory cells (T
    Language English
    Publishing date 2021-12-15
    Publishing country Germany
    Document type Journal Article ; Review
    ISSN 2719-4523
    ISSN (online) 2719-4523
    DOI 10.2478/rir-2021-0021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Peptide-based immunotherapy in lupus: Where are we now?

    P Singh, Ram / S Bischoff, David / S Singh, Satendra / H Hahn, Bevra

    Rheumatology and immunology research

    2023  Volume 4, Issue 3, Page(s) 139–149

    Abstract: In autoimmune rheumatic diseases, immune hyperactivity and chronic inflammation associate with immune dysregulation and the breakdown of immune self-tolerance. A continued, unresolved imbalance between effector and regulatory immune responses further ... ...

    Abstract In autoimmune rheumatic diseases, immune hyperactivity and chronic inflammation associate with immune dysregulation and the breakdown of immune self-tolerance. A continued, unresolved imbalance between effector and regulatory immune responses further exacerbates inflammation that ultimately causes tissue and organ damage. Many treatment modalities have been developed to restore the immune tolerance and immmunoregulatory balance in autoimmune rheumatic diseases, including the use of peptide-based therapeutics or the use of nanoparticles-based nanotechnology. This review summarizes the state-of-the-art therapeutic use of peptide-based therapies in autoimmune rheumatic diseases, with a specific focus on lupus.
    Language English
    Publishing date 2023-09-27
    Publishing country Germany
    Document type Journal Article ; Review
    ISSN 2719-4523
    ISSN (online) 2719-4523
    DOI 10.2478/rir-2023-0020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Identification and Contribution of Inflammation-Induced Novel MicroRNA in the Pathogenesis of Systemic Lupus Erythematosus.

    Singh, Ram P / Hahn, Bevra H / Bischoff, David S

    Frontiers in immunology

    2022  Volume 13, Page(s) 848149

    Abstract: Recently microRNAs (miRNAs) have been recognized as powerful regulators of many genes and pathways involved in the pathogenesis of inflammatory diseases including Systemic Lupus Erythematosus (SLE). SLE is an autoimmune disease characterized by ... ...

    Abstract Recently microRNAs (miRNAs) have been recognized as powerful regulators of many genes and pathways involved in the pathogenesis of inflammatory diseases including Systemic Lupus Erythematosus (SLE). SLE is an autoimmune disease characterized by production of various autoantibodies, inflammatory immune cells, and dysregulation of epigenetic changes. Several candidate miRNAs regulating inflammation and autoimmunity in SLE are described. In this study, we found significant increases in the expression of miR21, miR25, and miR186 in peripheral blood mononuclear cells (PBMCs) of SLE patients compared to healthy controls. However, miR146a was significantly decreased in SLE patients compared to healthy controls and was negatively correlated with plasma estradiol levels and with SLE disease activity scores (SLEDAI). We also found that protein levels of IL-12 and IL-21 were significantly increased in SLE patients as compared to healthy controls. Further, our data shows that protein levels of IL-12 were positively correlated with miR21 expression and protein levels of IL-21 positively correlated with miR25 and miR186 expression in SLE patients. In addition, we found that levels of miR21, miR25, and miR186 positively correlated with SLEDAI and miR146a was negatively correlated in SLE patients. Thus, our data shows a dynamic interplay between disease pathogenesis and miRNA expression. This study has translational potential and may identify novel therapeutic targets in patients with SLE.
    MeSH term(s) Humans ; Inflammation/genetics ; Inflammation/metabolism ; Interleukin-12/metabolism ; Leukocytes, Mononuclear ; Lupus Erythematosus, Systemic ; MicroRNAs/genetics ; MicroRNAs/metabolism
    Chemical Substances MIRN186 microRNA, human ; MIRN21 microRNA, human ; MIRN25 microRNA, human ; MicroRNAs ; Interleukin-12 (187348-17-0)
    Language English
    Publishing date 2022-04-04
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.848149
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Pregnancy in Women With Systemic Lupus Erythematosus: Messages for the Clinician.

    Hahn, Bevra H

    Annals of internal medicine

    2015  Volume 163, Issue 3, Page(s) 232–233

    MeSH term(s) Female ; Humans ; Lupus Erythematosus, Systemic/complications ; Pregnancy ; Pregnancy Complications ; Pregnancy Outcome
    Language English
    Publishing date 2015-08-04
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/M15-1301
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Effects of Peptide-Induced Immune Tolerance on Murine Lupus.

    Singh, Ram P / Hahn, Bevra H / Bischoff, David S

    Frontiers in immunology

    2021  Volume 12, Page(s) 662901

    Abstract: The regulation of autoimmunity and the molecular mechanisms by which different immune cells, including T cells, polymorphonuclear leukocytes (PMN-granulocytes), and B cells suppress autoimmune diseases is complex. We have shown previously that BWF1 lupus ...

    Abstract The regulation of autoimmunity and the molecular mechanisms by which different immune cells, including T cells, polymorphonuclear leukocytes (PMN-granulocytes), and B cells suppress autoimmune diseases is complex. We have shown previously that BWF1 lupus mice are protected from autoimmunity after
    MeSH term(s) Animals ; Antibodies, Antinuclear/immunology ; Autoimmunity ; B-Lymphocytes/immunology ; B-Lymphocytes/metabolism ; Biomarkers ; Disease Models, Animal ; Disease Susceptibility ; Gene Expression ; Granulocytes/immunology ; Granulocytes/metabolism ; Immune Tolerance/immunology ; Immunophenotyping ; Lupus Erythematosus, Systemic/genetics ; Lupus Erythematosus, Systemic/immunology ; Lupus Erythematosus, Systemic/metabolism ; Lymphocyte Activation/immunology ; Mice ; Mice, Inbred NZB ; Peptides/immunology ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism
    Chemical Substances Antibodies, Antinuclear ; Biomarkers ; Peptides
    Language English
    Publishing date 2021-05-19
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2021.662901
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Cellular and Molecular Phenotypes of pConsensus Peptide (pCons) Induced CD8

    Singh, Ram P / Hahn, Bevra H / Bischoff, David S

    Frontiers in immunology

    2021  Volume 12, Page(s) 718359

    Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with widespread inflammation, immune dysregulation, and is associated with the generation of destructive anti-DNA autoantibodies. We have shown previously the immune modulatory properties ...

    Abstract Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with widespread inflammation, immune dysregulation, and is associated with the generation of destructive anti-DNA autoantibodies. We have shown previously the immune modulatory properties of pCons peptide in the induction of both CD4
    MeSH term(s) Adult ; Aged ; Amino Acid Sequence ; Animals ; Antigens, Differentiation, T-Lymphocyte/genetics ; Antigens, Differentiation, T-Lymphocyte/metabolism ; Apoptosis/genetics ; Apoptosis/immunology ; CD8-Positive T-Lymphocytes/immunology ; Disease Models, Animal ; Epitopes, T-Lymphocyte/genetics ; Epitopes, T-Lymphocyte/immunology ; Female ; Gene Expression ; Healthy Volunteers ; Humans ; Immune Tolerance/genetics ; Lupus Erythematosus, Systemic/genetics ; Lupus Erythematosus, Systemic/immunology ; Mice ; Mice, Inbred NZB ; Middle Aged ; Peptides/administration & dosage ; Peptides/genetics ; Peptides/immunology ; RGS Proteins/genetics ; RGS Proteins/immunology ; T-Lymphocytes, Regulatory/immunology ; Young Adult
    Chemical Substances Antigens, Differentiation, T-Lymphocyte ; Epitopes, T-Lymphocyte ; Peptides ; RGS Proteins
    Language English
    Publishing date 2021-11-19
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2021.718359
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Interferon Genes Are Influenced by 17β-Estradiol in SLE.

    Singh, Ram P / Hahn, Bevra H / Bischoff, David S

    Frontiers in immunology

    2021  Volume 12, Page(s) 725325

    Abstract: Recent evidence suggests the existence of a nexus between inflammatory pathways and the female sex hormone 17β-estradiol, resulting in increased interferon-stimulated genes (ISGs), autoantibodies, and dysregulation of immune cells in SLE. However, the ... ...

    Abstract Recent evidence suggests the existence of a nexus between inflammatory pathways and the female sex hormone 17β-estradiol, resulting in increased interferon-stimulated genes (ISGs), autoantibodies, and dysregulation of immune cells in SLE. However, the molecular mechanisms and the effect of estradiol on candidate target genes and their pathways remains poorly understood. Our previous work suggests that female SLE patients have increased estradiol levels compared to healthy controls. In the present study, we explored the effects of 17β-estradiol treatment on expression of IFN (interferons)-stimulated genes and pro-inflammatory cytokines/chemokines. We found significantly increased (5-10-fold) expression of IFN-regulated genes in healthy females. Furthermore, we found significantly increased plasma levels of IL-6, IL-12, IL-17, IL-18, stem cell factor (SCF), and IL-21/IL-23 in SLE patients compared to healthy controls, and those levels positively correlated with the plasma levels of 17β-estradiol. In addition, levels of IL-21 positively correlated with the SLE disease activity index (SLEDAI) score of SLE patients.
    MeSH term(s) Adult ; Animals ; Case-Control Studies ; Chemokines/metabolism ; Cytokines/metabolism ; Estradiol/metabolism ; Estradiol/pharmacology ; Female ; Humans ; Interferons/genetics ; Interferons/metabolism ; Leukocytes, Mononuclear/drug effects ; Leukocytes, Mononuclear/immunology ; Linear Models ; Lupus Erythematosus, Systemic/immunology ; Lupus Erythematosus, Systemic/metabolism ; Male ; Mice ; Middle Aged ; Young Adult
    Chemical Substances Chemokines ; Cytokines ; Estradiol (4TI98Z838E) ; Interferons (9008-11-1)
    Language English
    Publishing date 2021-10-18
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2021.725325
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Should antibodies to high-density lipoprotein cholesterol and its components be measured in all systemic lupus erythematosus patients to predict risk of atherosclerosis?

    Hahn, Bevra H

    Arthritis and rheumatism

    2010  Volume 62, Issue 3, Page(s) 639–642

    MeSH term(s) Apolipoprotein A-I/immunology ; Atherosclerosis/etiology ; Autoantibodies/blood ; Cholesterol, HDL/immunology ; Humans ; Lupus Erythematosus, Systemic/blood ; Lupus Erythematosus, Systemic/complications ; Risk Factors
    Chemical Substances Apolipoprotein A-I ; Autoantibodies ; Cholesterol, HDL
    Language English
    Publishing date 2010-03
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 127294-9
    ISSN 1529-0131 ; 0004-3591 ; 2326-5191
    ISSN (online) 1529-0131
    ISSN 0004-3591 ; 2326-5191
    DOI 10.1002/art.27298
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Targeted therapies in systemic lupus erythematosus: successes, failures and future.

    Hahn, Bevra H

    Annals of the rheumatic diseases

    2011  Volume 70 Suppl 1, Page(s) i64–i66

    Abstract: Purpose: The author's goal is to review recent phase III clinical trials in patients with systemic lupus erythematosus (SLE), with emphasis on outcomes and on mechanisms by which the experimental drugs/biological agents suppress autoimmunity.: Methods! ...

    Abstract Purpose: The author's goal is to review recent phase III clinical trials in patients with systemic lupus erythematosus (SLE), with emphasis on outcomes and on mechanisms by which the experimental drugs/biological agents suppress autoimmunity.
    Methods: Prospective, randomised, controlled clinical trials in SLE published in the past 3 years identified in a PubMed search were reviewed, as well as abstracts describing similar but currently unpublished clinical trials presented at international meetings 2008-10.
    Conclusions: Two interventions have been proved in large multicentre prospective trials to be useful in the management of SLE: mycophenolate mofetil (equivalent to cyclophosphamide with a similar safety profile) and anti-BLyS (Benlysta), which was superior to placebo when added to background immunosuppression and did not appear to increase toxicity. The anti-BLyS trial outcome measure was an anchored composite index that required reduction of disease activity measure by the systemic lupus erythematosus disease activity index. Other trials that failed or the results of which are pending are also discussed.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Clinical Trials, Phase III as Topic ; Humans ; Immunosuppressive Agents/therapeutic use ; Lupus Erythematosus, Systemic/drug therapy ; Molecular Targeted Therapy/methods ; Mycophenolic Acid/analogs & derivatives ; Mycophenolic Acid/therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Immunosuppressive Agents ; belimumab (73B0K5S26A) ; Mycophenolic Acid (HU9DX48N0T)
    Language English
    Publishing date 2011-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/ard.2010.142208
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top